Tercica Report issue

Contributed to NME For profit Phase 3
Founded: Brisbane CA United States (2002)
Status: Acquired by Ipsen (2008)

Organization Overview

First Clinical Trial
2007
NCT00516386
First Marketed Drug
2005
mecasermin (Increlex)
First NDA Approval
2005
mecasermin (Increlex)
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Marketed Drugs (1)

mecasermin (Increlex) (2005 NDA)

Drugs in Phase 3 Trials (1)

mecasermin (Increlex) (3 trials)

Drugs in Other Trials (1)

somatropin (protropin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anorexia (Phase 2)

Anorexia Nervosa (Phase 2)

Crohn Disease (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2